METHODS AND RESULTS Patients included in a multicenter registry at 5 centers in Italy were systematically followed for major adverse cardiac events (MACE). Clinical data were obtained for 92 patients (mean age 57.1 years, 74.0% males) with a total of 95 lesions treated with overlapping Absorb BVS. Fifty-seven (61.9%) patients underwent scaffold implantation due to acute coronary syndrome. Diabetic patients were 17.3%. Multivessel disease was present in 63.0% of patients. Treated lesions were type B1 (21.3%), type B2 (23.0%), and type C (55.7%). Mean length covered by overlapping BVS was 48.0 AE16 mm. The mean number of implanted Absorb BVS was 2.25 scaffolds per lesion and 2.63 scaffolds per patient. Angiographic and procedural success occurred in all patients. At a median follow up of 10 months (interquartile range, 5-14.75 months), cumulative occurrence of MACE was 4.34%. Adverse events were: 1 possible late scaffold thrombosis (unexplained cardiac death occurring two months after elective revascularization), 2 TLR due to BVS restenosis (documented BVS recoil in 1 case), 1 TVR due to restenosis of drug eluting stent proximal to two overlapped scaffolds.
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2 Mayo Clinic, Phoenix, AZ BACKGROUND Percutaneous coronary intervention (PCI) of small vessels is associated with a high restenosis rate. Drug-eluting stents (DES) reduce restenosis in coronary arteries, but the role of DES in small coronary vessels has not been well defined. In our systematic review, we aim to summarize all known angiographic and clinical outcome of 2.25-mm DES, to highlight the need for specific outcome data in this cohort.
METHODS A systematic literature search of 394 relevant citations from PubMed, EMBASE, Web of Science and the Cochrane Central Register of Controlled Trials yielded 8 eligible studies studying FDA approved 2.25-mm DES. Angiographic and clinical outcome data were extracted and compared between each type of DES. Subgroup analysis comparing clinical outcome between sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) was done using a random effects model.
RESULTS
Of the 8 studies included in the analysis, 6 were non-randomized and 2 were randomized against bare-metal stents (BMS). A total of 1,037 patients were studied, with follow-up ranging from 1 month to 5 years. PES, SES and everolimuseluting stents (EES) were studied. Myocardial infarction at one year was highest in PES vs. SES and EES: 4.2% vs. 3.4% and 1.5%. Target vessel revascularization at one year was highest in PES vs. SES and EES: 13.8% vs. 5.7% and 8.8%. Death rate was highest in PES at 4.2% vs. SES and EES (3.4% and 1.5%). Mean late lumen loss for PES, SES, and EES was 0.28AE0.11 mm, 0.15AE0.11 mm, and 0.16AE0.41 mm at 9 months to 1 year. Mean diameter stenosis for PES, SES and EES was 34.7AE4.2%, 29.5AE6.2%, and 20.9AE22.5%. Mean binary stenosis for PES, SES and EES was 26.9AE7.8%, 10.4AE6.7%, and 9.6% respectively. No 2.25 mm specific data was available for zotarolimus eluting stents, which was reported in combination with larger stent sizes.
CONCLUSION Our composite data suggest that 2.25-mm SES and EES have superior clinical and angiographic outcomes compared with 2.25-mm PES, which has been shown to be superior to BMS in a randomized controlled study. Given the unique theoretical challenges posed by small vessel PCI, the overall lack of randomized data in this cohort needs to be addressed with future studies evaluating 2.25 mm stents in next-generation DES.
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Comparison RESULTS After PSM analysis, 2 propensity-matched groups (149 pairs, n ¼ 298 pts, Cstatistic¼0.793) were generated and the baseline characteristics of the two groups were balanced. Six to 9-month angiographic outcomes showed that the incidence of binary in-stent restenosis was higher in the BES group than PtCr-EES (18.9% vs. 7.0%, p¼0.034). This adverse angiographic outcomes were translated into worse 12-month clinical outcomes; the incidence of target lesion revascularizations (TLR: HR; 3.879, C.I; 1.06-14.2, p¼0.041) and TLR-MACE (HR; 3.465, C.I; 1.103-10.88, p¼0.033) BA9 were significantly higher than PtCr-EES despite of similar incidence of mortality and myocardial infarction.
CONCLUSIONS As compared with PtCr-EES, BES seem to be associated with higher rate of TLR and TLR MACE up to 12-month in a series of Asian population in real world clinical practice. METHODS We hypothesized that thin, bare metal cobalt chromium or platinum chromium stents modified with an ultra-hydrophilic surface (UHS) treatment could reduce late intimal hyperplasia (IH) as with second-generation DES, yet maintain fast healing akin to bare metal stents (BMS). To test this, commercially available, FDAapproved DES and BMS were compared with UHS in A) porcine coronary models to assess IH and late thrombosis; and B) a rabbit iliac model to assess early healing and subacute thrombosis.
RESULTS
In vitro tests demonstrated similar to faster endothelialization with reduced platelet adhesion (97% reduction, p<0.001) compared with untreated BMS. Hydrophilic treatment reduced IH in porcine coronary arteries relative to 3 corresponding BMS and DES platforms (2-3-fold reduction in 30-day angiographic restenosis; p<0.03). In contrast to early healing of UHS and BMS (porcine 30-day endothelialization score uniformly 4.0 of 4.0; confirmed in rabbit), DES trended to delayed healing at one month (range 2.67 to 4.0 out of 4.0) that resolved by 3 months, correlating with computed drug-receptor saturation. Elevation in thrombotic indices correlated with reduced endothelialization (p<0.0002) and occurred most often with DES, never with UHS (Poisson probability¼0.135).
CONCLUSION Ultra-hydrophilic surface treatment of contemporary stents conferred excellent healing while moderating neointimal and thrombotic responses. With
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a clinical trial under way (clinicaltrials.gov ID: NCT02176265), such surfaces may offer safe alternatives to DES, particularly in patients in whom rapid healing is crucial.
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Comparison METHODS A total of 626 patients (pts) receiving BES or ZES were pooled from our prospective percutaneous coronary intervention (PCI) registry from March 2008 to May 2013. To adjust potential confounders, a propensity score matched (PSM) analysis was performed using the logistic regression model, and clinical outcomes were compared between the two groups up to 12-month.
RESULTS After PSM analysis, 2 propensity-matched groups (135 pairs, n ¼ 270 pts, C-statistic¼0.809) were generated and the baseline characteristics of the two groups were balanced. At six to 9-month angiographic and Two-year clinical outcomes, there were similar incidence of binary in-stent restenosis and hard endpoints including mortality, myocardial infarction, target lesion revascularization (TLR), target vessel revascularization (TVR), non-target vessel revascularization (NTVR) and major adverse cardiac events (MACEs ,Table) .
CONCLUSIONS In our study, BES showed similar efficacy and safety compared with ZES up to 12-months in a series of Asian population in real world clinical practice. BACKGROUND Wave Intensity Analysis (WIA) has found particular applicability in the coronary circulation where it is able to quantify and qualify the energy affecting blood flow. The most important wave for the regulation of coronary blood flow is the backward-travelling decompression wave (BDW). Until now, coronary WIA has always been calculated from invasive measures of pressure and flow. However, recently it has become feasible to obtain coronary pressure and flow waveforms non-invasively. In this study we set out to validate non-invasive coronary wave intensity at rest and under exercise conditions.
METHOD AND RESULTS 22 patients (mean age 60AE12, 14 male) with unobstructed coronary arteries, underwent invasive WIA in the left anterior descending artery. Immediately afterwards, non-invasive coronary flow and pressure were recorded and WIA calculated from pulsed-wave Doppler echocardiography and brachial suprasystolic blood pressure. 9 of these patients also underwent non-invasive WIA assessment during a standardized exercise regimen.
A consistent pattern of 6 predominating waves were observed both invasively and non-invasively with a very similar BDW (peak: -13.8AE7.9 vs -14.9AE7. CONCLUSION Coronary wave intensity analysis can be reliably measured non-invasively and responds appropriately in physiological and pathological settings. This has potential to simplify WIA assessments and increase its applicability.
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